# Capricor Therapeutics, Inc.: overview CAPR · Nasdaq · CIK 1133869 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/capr.md) · [Financials](/companies/capr/financials.md) · [Filings](/companies/capr/filings.md) · [Insiders](/companies/capr/insiders.md) Latest reported revenue: [$11.1m](/filings/0001104659-26-029580.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Mar 17, 2026 (XBRL us-gaap:Revenues, accession 0001104659-26-029580). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.3](/filings/0001104659-25-109298.md) | [11.1 d](/filings/0001104659-26-029580.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(575.2%)](/filings/0001104659-25-109298.md) | [(69.1%) d](/filings/0001104659-26-029580.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(555.2%)](/filings/0001104659-25-109298.md) | [(63.9%) d](/filings/0001104659-26-029580.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.38)](/filings/0001104659-25-109298.md) | not reported | [(0.53)](/filings/0001104659-26-060382.md) | [(0.57)](/filings/0001104659-26-097294.md) | [(0.54)](/filings/0001104659-25-109298.md) | not reported | [(0.59)](/filings/0001104659-26-060382.md) | [(0.70)](/filings/0001104659-26-097294.md) | | Free cash flow | $m | [(11.7) d](/filings/0001104659-25-109298.md) | [(15.3) d](/filings/0001104659-26-029580.md) | [(7.3)](/filings/0001104659-26-060382.md) | [(20.4) d](/filings/0001104659-26-097294.md) | [(19.7) d](/filings/0001104659-25-109298.md) | [(25.2) d](/filings/0001104659-26-029580.md) | [(34.4)](/filings/0001104659-26-060382.md) | [(35.5) d](/filings/0001104659-26-097294.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0001558370-23-004124.md) | [2.6](/filings/0001558370-24-002861.md) | [25.2](/filings/0001558370-25-003707.md) | [22.3](/filings/0001104659-26-029580.md) | [0.0](/filings/0001104659-26-029580.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(8549.9%)](/filings/0001558370-23-004124.md) | [(1163.9%)](/filings/0001558370-24-002861.md) | [(95.6%)](/filings/0001558370-25-003707.md) | [(191.1%)](/filings/0001104659-26-029580.md) | not reported | | Net margin | % | [(8175.9%)](/filings/0001558370-23-004124.md) | [(1137.4%)](/filings/0001558370-24-002861.md) | [(88.5%)](/filings/0001558370-25-003707.md) | [(181.7%)](/filings/0001104659-26-029580.md) | not reported | | Diluted EPS | $ per share | [(0.87)](/filings/0001558370-23-004124.md) | [(1.18)](/filings/0001558370-24-002861.md) | [(0.83)](/filings/0001558370-25-003707.md) | [(1.15)](/filings/0001104659-26-029580.md) | [(2.26)](/filings/0001104659-26-029580.md) | | Free cash flow | $m | [(18.0)](/filings/0001558370-23-004124.md) | [2.9](/filings/0001558370-24-002861.md) | [(26.9)](/filings/0001558370-25-003707.md) | [(41.2)](/filings/0001104659-26-029580.md) | [(72.7)](/filings/0001104659-26-029580.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/capr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $99.8m | 4,145,061 | | Added +723,246 | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $98.7m | 4,099,900 | | Added +700,000 | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $98.6m | 4,092,784 | | Added +274,184 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $81.8m | 3,397,150 | | Added +1,215,249 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $55.3m | 2,297,674 | | Added +269,942 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $38.0m | 1,578,131 | | Added +666,155 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $36.3m | 1,507,844 | | Unchanged | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $33.6m | 1,395,156 | | Added +805,156 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $33.0m | 1,372,286 | | Added +253,960 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $27.4m | 1,137,730 | | Added +365,081 | ## Recent filings [All 838 filings](/companies/capr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-24 | 13:25 ET | [8-K](/filings/0001104659-26-100071.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-100071 | | 2026-08-14 | 20:46 ET | [10-Q](/filings/0001104659-26-097294.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097294 | | 2026-08-13 | 20:07 ET | [8-K](/filings/0001104659-26-095908.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-095908 | | 2026-07-30 | 20:05 ET | [8-K](/filings/0001104659-26-088667.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-088667 | | 2026-07-29 | 14:05 ET | [8-K](/filings/0001104659-26-087891.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-087891 | | 2026-07-14 | 21:06 ET | [8-K](/filings/0001104659-26-083559.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-26-083559 | | 2026-06-26 | 21:15 ET | [8-K](/filings/0001104659-26-078327.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-078327 | | 2026-06-08 | 20:05 ET | [8-K](/filings/0001104659-26-071364.md) | 5.07 Shareholder vote results | 0001104659-26-071364 | | 2026-05-13 | 21:20 ET | [10-Q](/filings/0001104659-26-060382.md) | Quarterly report, period 2026-03-31 | 0001104659-26-060382 | | 2026-05-12 | 20:06 ET | [8-K](/filings/0001104659-26-059380.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-059380 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-029580.md), filed Mar 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1133869 - Tickers: CAPR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.